Express News | CorMedix Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 14, 2024
CORMEDIX INC. TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 14, 2024
Truist Securities Maintains Buy on Cormedix, Lowers Price Target to $12
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating, Cuts Target Price to $12
Express News | CorMedix Inc : Truist Securities Cuts Target Price to $12 From $14
Express News | CorMedix Inc. Announces Outpatient Availability of Defencath
CorMedix Inc. Announces Outpatient Availability of DefenCath
CORMEDIX INC. ANNOUNCES OUTPATIENT AVAILABILITY OF DEFENCATH
Truist Financial Initiates CorMedix(CRMD.US) With Buy Rating
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $10
CorMedix to Start DefenCath Label Expansion Program This Year
CorMedix: FDA Issues Feedback On Request Regarding DefenCath - Quick Facts
Express News | CorMedix Receives FDA Support for Expanded Indication of DefenCath in Adult TPN Patients; Plans to Submit Clinical Protocol in Q3 2024 and Initiate Program by Year-End
Express News | CorMedix Inc. Receives FDA Feedback on Potential Label Expansion
CORMEDIX INC. RECEIVES FDA FEEDBACK ON POTENTIAL LABEL EXPANSION
JMP Securities Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $19
Express News | CorMedix Announces CMS Grants Pass-Through Status For DefenCath Under Hospital Outpatient Prospective Payment System (OPPS)
CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath
CORMEDIX INC. ANNOUNCES CMS GRANTS PASS-THROUGH STATUS TO DEFENCATH
CorMedix Secures Strong Market Position With Successful DefenCath Launch and Strategic Supply Agreements
No Data